|
Title
|
Published
|
Price
|
|
Cell-Based Assays for Drug Discovery
By: Trimark Publications
The area of drug discovery tools is one of the newest and most important sectors of pharmaceutical research and development. The term drug discovery tools usually refers to high-content screening (HCS) and analysis and is
|
more...
|
8/1/2009
|
$3,400.00
|
|
Delivering RNAi-Based Therapeutics & Diagnostics: Challenges & Opportunities
By: PharmaVision
This cutting edge & insightful report can be used to interpret & assess the potential of RNAi-based medicines. It provides opinions & market projections to:
assess the commercial potential of RNAi-based therapies in all
|
more...
Search inside this report
|
7/1/2009
|
$1,566.00
|
|
The Future of RNAi Therapeutics: Drug Pipelines and Prospects
By: Business Insights
"The Future of RNAi Therapeutics: Drug pipelines and prospects
""The total RNAi therapy market is estimated to value $580m by 2012. This forecast is based upon current treatments, levels of market satisfaction and
|
more...
Search inside this report
|
9/1/2008
|
$3,835.00
|
|
Realizing the Promise of Therapeutic RNAi: Emerging Strategies for RNAi Delivery
By: Decision Resources
The discovery of RNA interference (RNAi) has renewed interest in developing nucleic acid drugs based on
targeting messenger RNAs (mRNAs). This field of research offers the potential to produce low-dose, nontoxic
RNAi agents to treat
|
more...
|
1/31/2008
|
$1,125.00
|
|
RNAi Therapeutics 2008
By: Select Biosciences Limited
This is the latest RNAi-based Therapeutics Market Report from Select Biosciences. This report presents an up-to-date thorough analysis of the RNAi therapeutics landscape based upon our continuing coverage of this dynamic marketplace. This report presents
|
more...
|
11/1/2007
|
$3,870.00
|
|
Clinical Forecasting: A Novel Bayesian Tool for Predicting Phase III Outcomes
By: CHI Insight Pharma Reports
In recent years, there has been an explosion in predictive technologies to help researchers select only the most promising candidates for clinical development. The need for such tools is driven by the disastrous economic consequences
|
more...
|
7/1/2007
|
$2,500.00
|
|
Outlook For Rnai, 2007: Sirna And Mirna In Biology, Diagnostics And Therapeutics
By: Business Insights
Report overview
RNAi-based screens have provided new opportunities for the discovery and validation of novel therapeutic targets in areas such as cancer and infectious diseases. Since 2005, enormous strides have also been made in the
|
more...
Search inside this report
|
6/1/2007
|
$2,875.00
|
|
High Content Analysis 2007
By: Select Biosciences Limited
This report presents an industry analysis of the High-Content Analysis Marketplace in both qualitative and quantitative terms. High-Content Analysis involves the use of instrumentation, reagents, and informatics to perform multi-parametric analysis of biological systems—ie., lots
|
more...
|
4/1/2007
|
$2,500.00
|
|
RNAi/Nicro RNA Market Report
By: Select Biosciences Limited
This report presents an industry analysis of the RNAi and microRNA markets in both qualitative and quantitative terms. Select Biosciences’ industry tracking of these spaces involves analyses of the technology trends as well as market
|
more...
|
2/1/2007
|
$2,500.00
|
|
Optimizing Synthetic RNAi: Perspectives from the Pharmaceutical and Biotech Industry
By: BioInformatics, LLC
This report identifies the RNAi research objectives of pharmaceutical and biotech scientists and present siRNA customer purchasing preferences by key experimental design parameters
|
more...
|
12/1/2006
|
$500.00
|
|
Taking the Pharma Lead on RNAi: Merck Bets on Sirna
By: IDC
This Health Industry Insights Perspective describes analyst perspectives on the implications of Merck's recent decision to acquire Sirna Therapeutics Inc. for $1.1 billion. Merck's expansion of its efforts to develop and exploit new therapeutics
|
more...
Search inside this report
|
11/20/2006
|
$500.00
|
|
Biologic Drugs To Drive Pharmaceutical Market Growth
By: Datamonitor
Introduction As patent expiries take their toll on small molecule blockbuster drugs Big Pharma are turning to biologic therapies to drive future growth. Alliances and partnerships will be a key strategy in gaining access to the
|
more...
Search inside this report
|
10/3/2006
|
$1,695.00
|
|
Gene Silencing with RNA Interference: A New Generation of Pharmaceuticals?
By: Patent Insights, Inc.
The market for RNA interference (RNAi) both as a research tool and as a new class of pharmaceuticals is projected to explode, but is the technology ready to support the expected growth? The purpose
|
more...
|
7/20/2006
|
$4,950.00
|
|
U.S. RNAi Markets
By: Frost & Sullivan
Research Overview
This Frost & Sullivan research service entitled U.S. RNAi Markets provides revenue forecasts for individual market sectors as well as overall market, detailed market trends with specific applications forecasts, and market-wide challenge
|
more...
|
5/9/2006
|
$6,000.00
|
|
The Exploding RNAi Market- Translating the Genome into a Large Market by 2009
By: Fuji-Keizai USA, Inc.
Since its discovery in 1998 by two scientists, the naturally occurring RNA interference effect has been hailed as the hottest technical breakthrough in biological research in the last decade. It may even surpass PCR
|
more...
|
2/13/2006
|
$1,295.00
|
|
RNAi Therapeutics: Challenges in Drug Development and Delivery
By: CHI Insight Pharma Reports
Interfering RNA (RNAi) offers tremendous therapeutic promise. This report:
Evaluates the prospects for curing disease using RNAi.
Examines the pros and cons of all the major known methods of delivering RNAi.
Describes advances in
|
more...
|
10/1/2005
|
$2,750.00
|
|
2005 RNAi Report: A Revolutionary Technology
By: Biocompare
Key applications for RNAi research in functional genomics are target validation, basic research, and therapeutics. The markets for each of these applications are growing rapidly and are forecasted to continue growing for the next
|
more...
|
7/20/2005
|
$2,000.00
|
|
The Outlook For RNAi: Accelerating Drug Discovery And The Development Of RNAi Therapeutics
By: Business Insights
While the human genome project has provided vast amounts of sequence information, the in vivo functional analysis of thousands of genes has presented a significant challenge to researchers and to pharmaceutical companies in the discovery
|
more...
Search inside this report
|
5/1/2005
|
$2,875.00
|
|
Emerging Drug Discovery Technologies: Building Competitive Advantage Through Lab-on-aChip, Nanotechnology and RNAi
By: Business Insights
The last decade has been marked by an unprecedented boom in the number and variety of technologies used to discover and develop new drugs; many of these technologies arose from work surrounding the human genome
|
more...
Search inside this report
|
4/1/2005
|
$2,875.00
|
|
RNAi: Broad Application, Expansive Opportunity, 2nd Edition
By: Drug and Market Development Publishing
Dr. Edward Weck Dr. Weck has extensive experience in industry, technology transfer, and as a consultant. Following work in Germany and California cloning starch control genes, he worked on vectors for corn transformation. This
|
more...
Search inside this report
|
1/5/2005
|
$2,495.00
|
|
Nucleic Acid-Based Therapeutics: World Markets, Developments, and Applications
By: Kalorama Information
The concept of nucleic acid-based therapeutics is not a new one. For a long time it has been thought that molecules similar to those that make up our genetic structure would make effective therapeutics.
|
more...
Buy by the section | Search inside this report
|
1/1/2005
|
$3,500.00
|
|
Advances in RNAi--A Global Technology Assessment (Technical Insights)
By: Frost & Sullivan
Transfecting RNAi into Target Cells Proves to be a Significant Challenge
Delivering or transfecting ribonucleic acid interference (RNAi) into mammalian cells is one of the biggest challenges facing researchers. In addition, a tedious
|
more...
|
11/19/2004
|
$4,550.00
|
|
High-Content Analysis Market Outlook
By: CHI Insight Pharma Reports
High-Content Analysis Market Outlook quantifies the current and future market size for high-content a nalysis (HCA) systems, software, and reagents. Key areas of implementation and growth potential, as well as areas of future development that
|
more...
|
3/1/2004
|
$2,500.00
|
|
Antivirals-A broad market overview
By: Datamonitor
Introduction
While each viral indication, ranging from HIV to influenza, presents unique challenges, there are a number of issues that companies developing and marketing drugs across this field face. Curative therapies are rare, drug resistance
|
more...
Search inside this report
|
8/22/2003
|
$1,900.00
|
|
Antisense Products: Technology, Markets
By: BCC Research
REASONS FOR THE STUDY
The use of antisense compounds as therapeutics has become increasing popular in the past few years. With the completion of the sequencing of the human genome, antisense offers
|
more...
Search inside this report
|
3/1/2003
|
$4,198.00
|
|
Title
|
Published
|
Price
|
(0 items)
